{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:56:34Z","timestamp":1781776594488,"version":"3.54.5"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the General Program of National Natural Science Foundation of China","award":["72174207"],"award-info":[{"award-number":["72174207"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15916-4","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T05:06:52Z","timestamp":1774760812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing treatment and sequencing strategies for maximal survival and net health benefits in ALK-positive NSCLC: a systematic review and reconstructed individual patient data meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Mingye","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqiao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"issue":"2","key":"15916_CR1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","volume":"12","author":"W Pao","year":"2011","unstructured":"Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175\u201380.","journal-title":"Lancet Oncol"},{"issue":"3","key":"15916_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"15916_CR3","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623\u201340.","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"15916_CR4","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","volume":"36","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line Crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol. 2018;36(22):2251\u20138.","journal-title":"J Clin Oncol"},{"issue":"10072","key":"15916_CR5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"JC Soria","year":"2017","unstructured":"Soria JC, Tan D, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917\u201329.","journal-title":"Lancet"},{"issue":"10","key":"15916_CR6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","volume":"13","author":"YL Wu","year":"2018","unstructured":"Wu YL, Lu S, Lu Y, et al. Results of PROFILE 1029, a Phase III comparison of first-line Crizotinib versus chemotherapy in East Asian Patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(10):1539\u201348.","journal-title":"J Thorac Oncol"},{"issue":"10089","key":"15916_CR7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","volume":"390","author":"T Hida","year":"2017","unstructured":"Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29\u201339.","journal-title":"Lancet"},{"issue":"9","key":"15916_CR8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829.","journal-title":"N Engl J Med"},{"key":"15916_CR9","doi-asserted-by":"crossref","unstructured":"Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Resp Med. 2019;7(5):437\u201346.","DOI":"10.1016\/S2213-2600(19)30053-0"},{"issue":"21","key":"15916_CR10","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027\u201339.","journal-title":"N Engl J Med"},{"issue":"7","key":"15916_CR11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Kim TM, Crino L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874\u201386.","journal-title":"Lancet Oncol"},{"issue":"25","key":"15916_CR12","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.","journal-title":"N Engl J Med"},{"issue":"11","key":"15916_CR13","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","volume":"7","author":"L Horn","year":"2021","unstructured":"Horn L, Wang Z, Wu G, et al. Ensartinib vs Crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol. 2021;7(11):1617\u201325.","journal-title":"JAMA Oncol"},{"issue":"23","key":"15916_CR14","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377.","journal-title":"N Engl J Med"},{"issue":"21","key":"15916_CR15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, et al. First-line Lorlatinib or Crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018\u201329.","journal-title":"N Engl J Med"},{"key":"15916_CR16","doi-asserted-by":"crossref","unstructured":"Yang J, Lu S, Burotto M. 319O ALTA-3: a randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC. 2022.","DOI":"10.1016\/j.annonc.2022.10.356"},{"issue":"1","key":"15916_CR17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41392-023-01538-w","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Min J, Yang N, et al. Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial. Signal Transduct Target Ther. 2023;8(1):301.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"15916_CR18","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056\u201364.","journal-title":"Ann Oncol"},{"issue":"12","key":"15916_CR19","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16(12):2091\u2013108.","journal-title":"J Thorac Oncol"},{"issue":"17suppl","key":"15916_CR20","doi-asserted-by":"crossref","first-page":"LBA8503","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8503","volume":"42","author":"BJ Solomon","year":"2024","unstructured":"Solomon BJ, Liu G, Felip E, et al. Lorlatinib vs crizotinib in treatment-na\u00efve patients with advancedALK\u2009+\u2009non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study. J Clin Oncol. 2024;42(17suppl):LBA8503.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15916_CR21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41392-023-01538-w","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Min J, Yang N, et al. Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial. Signal Transduct Target Ther. 2023;8(1):301.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"15916_CR22","doi-asserted-by":"crossref","first-page":"100333","DOI":"10.1016\/j.esmoop.2021.100333","volume":"7","author":"J Wolf","year":"2022","unstructured":"Wolf J, Helland A, Oh IJ, et al. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open. 2022;7(1):100333.","journal-title":"ESMO Open"},{"issue":"12","key":"15916_CR23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","volume":"18","author":"JC Yang","year":"2023","unstructured":"Yang JC, Liu G, Lu S, et al. Brigatinib versus Alectinib in ALK-Positive NSCLC after disease progression on Crizotinib: results of phase 3 ALTA-3 trial. J Thorac Oncol. 2023;18(12):1743\u201355.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"15916_CR24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12916-023-02738-5","volume":"21","author":"Y Shi","year":"2023","unstructured":"Shi Y, Chen J, Zhang H, et al. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). BMC Med. 2023;21(1):72.","journal-title":"BMC Med"},{"issue":"1","key":"15916_CR25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(19)30252-8","volume":"8","author":"Y Yang","year":"2020","unstructured":"Yang Y, Zhou J, Zhou J, et al. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial Lancet Respir Med. 2020;8(1):45\u201353.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"15916_CR26","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2022.02.014","volume":"17","author":"S Lu","year":"2022","unstructured":"Lu S, Zhou Q, Liu X, et al. Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a phase 2 study in People\u2019s Republic of China. J Thorac Oncol. 2022;17(6):816\u201326.","journal-title":"J Thorac Oncol"},{"issue":"13","key":"15916_CR27","doi-asserted-by":"crossref","first-page":"21903","DOI":"10.18632\/oncotarget.15746","volume":"8","author":"M Duruisseaux","year":"2017","unstructured":"Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903\u201317.","journal-title":"Oncotarget"},{"key":"15916_CR28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2020.12.026","volume":"145","author":"K Ito","year":"2021","unstructured":"Ito K, Yamanaka T, Hayashi H, et al. Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): a multicenter retrospective cohort study. Eur J Cancer. 2021;145:183\u201393.","journal-title":"Eur J Cancer"},{"issue":"4","key":"15916_CR29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jtho.2018.12.014","volume":"14","author":"JM Pacheco","year":"2019","unstructured":"Pacheco JM, Gao D, Smith D, et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol. 2019;14(4):691\u2013700.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"15916_CR30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000529824","volume":"12","author":"D Tan","year":"2023","unstructured":"Tan D, Tang A, Lim WH, et al. Survival trends in sorafenib for advanced hepatocellular carcinoma: a reconstructed individual patient data meta-analysis of randomized trials. Liver Cancer. 2023;12(5):445\u201356.","journal-title":"Liver Cancer"},{"issue":"1","key":"15916_CR31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0163278702025001006","volume":"25","author":"LA Stewart","year":"2002","unstructured":"Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof. 2002;25(1):76\u201397.","journal-title":"Eval Health Prof"},{"issue":"12","key":"15916_CR32","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","volume":"5","author":"CH Tseng","year":"2020","unstructured":"Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1039\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"15916_CR33","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.14309\/ctg.0000000000000236","volume":"11","author":"KS Cheung","year":"2020","unstructured":"Cheung KS, Mak LY, Liu SH, et al. Entecavir vs Tenofovir in hepatocellular carcinoma prevention in chronic hepatitis b infection: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2020;11(10):e236.","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"15916_CR34","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","volume":"19","author":"WM Choi","year":"2021","unstructured":"Choi WM, Choi J, Lim YS. Effects of Tenofovir vs Entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(2):246\u201358.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"15916_CR35","doi-asserted-by":"crossref","first-page":"1051484","DOI":"10.3389\/fpubh.2023.1051484","volume":"11","author":"M Zhao","year":"2023","unstructured":"Zhao M, Shao T, Chi Z, et al. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: a sequential model. Front Public Health. 2023;11:1051484.","journal-title":"Front Public Health"},{"key":"15916_CR36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"issue":"7","key":"15916_CR37","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jval.2020.03.010","volume":"23","author":"A Wiksten","year":"2020","unstructured":"Wiksten A, Hawkins N, Piepho HP, et al. Nonproportional hazards in network meta-analysis: efficient strategies for model building and analysis. Value Health. 2020;23(7):918\u201327.","journal-title":"Value Health"},{"issue":"5","key":"15916_CR38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/09622802211070253","volume":"31","author":"SC Freeman","year":"2022","unstructured":"Freeman SC, Cooper NJ, Sutton AJ, et al. Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: application to a melanoma network. Stat Methods Med Res. 2022;31(5):839\u201361.","journal-title":"Stat Methods Med Res"},{"issue":"23","key":"15916_CR39","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","volume":"33","author":"LE Schnipper","year":"2015","unstructured":"Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563\u201377.","journal-title":"J Clin Oncol"},{"key":"15916_CR40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"15916_CR41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/sim.3602","volume":"29","author":"D Jackson","year":"2010","unstructured":"Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird\u2019s methodology to perform multivariate random effects meta-analyses. Stat Med. 2010;29(12):1282\u201397.","journal-title":"Stat Med"},{"key":"15916_CR42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152.","journal-title":"BMC Med Res Methodol"},{"issue":"22","key":"15916_CR43","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","volume":"32","author":"H Uno","year":"2014","unstructured":"Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32(22):2380\u20135.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15916_CR44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/biom.12384","volume":"72","author":"L Zhao","year":"2016","unstructured":"Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. Biometrics. 2016;72(1):215\u201321.","journal-title":"Biometrics"},{"key":"15916_CR45","doi-asserted-by":"crossref","first-page":"105931","DOI":"10.1016\/j.phrs.2021.105931","volume":"174","author":"B Zhao","year":"2021","unstructured":"Zhao B, Han Y, Wang Y, et al. A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer. Pharmacol Res. 2021;174:105931.","journal-title":"Pharmacol Res"},{"issue":"3","key":"15916_CR46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s41669-023-00391-5","volume":"7","author":"T Shao","year":"2023","unstructured":"Shao T, Zhao M, Liang L, et al. Impact of extrapolation model choices on the structural uncertainty in economic evaluations for cancer immunotherapy: a case study of checkmate 067. Pharmacoecon Open. 2023;7(3):383\u201392.","journal-title":"Pharmacoecon Open"},{"issue":"5","key":"15916_CR47","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.32411","volume":"76","author":"T Ivanics","year":"2022","unstructured":"Ivanics T, Murillo PC, Claasen M, et al. Dynamic risk profiling of HCC recurrence after curative intent liver resection. Hepatology. 2022;76(5):1291\u2013301.","journal-title":"Hepatology"},{"key":"15916_CR48","doi-asserted-by":"crossref","first-page":"569500","DOI":"10.3389\/fpubh.2020.569500","volume":"8","author":"A Carta","year":"2020","unstructured":"Carta A, Conversano C. On the Use of Markov Models in pharmacoeconomics: pros and cons and implications for policy makers. Front Public Health. 2020;8:569500.","journal-title":"Front Public Health"},{"issue":"1","key":"15916_CR49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","volume":"38","author":"C Smare","year":"2020","unstructured":"Smare C, Lakhdari K, Doan J, et al. Evaluating Partitioned Survival and Markov Decision-Analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. PharmacoEconomics. 2020;38(1):97\u2013108.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"15916_CR50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12916-023-02738-5","volume":"21","author":"Y Shi","year":"2023","unstructured":"Shi Y, Chen J, Zhang H, et al. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). BMC Med. 2023;21(1):72.","journal-title":"BMC Med"},{"issue":"1","key":"15916_CR51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41392-023-01538-w","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Min J, Yang N, et al. Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial. Signal Transduct Target Ther. 2023;8(1):301.","journal-title":"Signal Transduct Target Ther"},{"key":"15916_CR52","volume-title":"Guide to the Methods of Technology Appraisal 2013","author":"N Excellence","year":"2013","unstructured":"Excellence N I F H. Guide to the Methods of Technology Appraisal 2013. London: National Institute for Health and Care Excellence (NICE); 2013."},{"issue":"23","key":"15916_CR53","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","volume":"33","author":"LE Schnipper","year":"2015","unstructured":"Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563\u201377.","journal-title":"J Clin Oncol"},{"key":"15916_CR54","unstructured":"Brigatinib for ALK-positive advanced nonsmall-cell lung cancer that has not been previously treated with an ALK inhibitor [EB\/OL]. [2024-03-12]. https:\/\/www.nice.org.uk\/guidance\/ta670\/evidence\/final-appraisal-determination-committee-papers-pdf-8964111853."},{"issue":"1","key":"15916_CR55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000520278","volume":"11","author":"G Cabibbo","year":"2022","unstructured":"Cabibbo G, Reig M, Celsa C, et al. First-Line immune checkpoint inhibitor-based sequential therapies for advanced hepatocellular carcinoma: rationale for future trials. Liver Cancer. 2022;11(1):75\u201384.","journal-title":"Liver Cancer"},{"issue":"14","key":"15916_CR56","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1200\/JCO.2016.70.5749","volume":"35","author":"T Tamura","year":"2017","unstructured":"Tamura T, Kiura K, Seto T, et al. Three-year follow-up of an Alectinib Phase I\/II study in ALK-positive non-small-cell lung cancer: AF-001JP. J Clin Oncol. 2017;35(14):1515\u201321.","journal-title":"J Clin Oncol"},{"issue":"7","key":"15916_CR57","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","volume":"34","author":"SH Ou","year":"2016","unstructured":"Ou SH, Ahn JS, De Petris L, et al. Alectinib in Crizotinib-Refractory ALK-Rearranged non-small-cell lung cancer: a Phase II Global Study. J Clin Oncol. 2016;34(7):661\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15916_CR58","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtho.2019.11.004","volume":"15","author":"RM Huber","year":"2020","unstructured":"Huber RM, Hansen KH, Paz-Ares RL, et al. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year follow-up on systemic and intracranial outcomes in the Phase 2 ALTA trial. J Thorac Oncol. 2020;15(3):404\u201315.","journal-title":"J Thorac Oncol"},{"issue":"24","key":"15916_CR59","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","volume":"34","author":"L Crino","year":"2016","unstructured":"Crino L, Ahn MJ, De Marinis F, et al. Multicenter Phase II study of whole-body and intracranial activity with Ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and Crizotinib: results From ASCEND-2. J Clin Oncol. 2016;34(24):2866\u201373.","journal-title":"J Clin Oncol"},{"issue":"4","key":"15916_CR60","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jtho.2019.11.006","volume":"15","author":"M Nishio","year":"2020","unstructured":"Nishio M, Felip E, Orlov S, et al. Final overall survival and other efficacy and safety results from ASCEND-3: Phase II study of Ceritinib in ALKi-naive patients with ALK-rearranged NSCLC. J Thorac Oncol. 2020;15(4):609\u201317.","journal-title":"J Thorac Oncol"},{"key":"15916_CR61","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2020.10.024","volume":"150","author":"YL Wu","year":"2020","unstructured":"Wu YL, Shi Y, Tan D, et al. Phase 1\/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. Lung Cancer. 2020;150:240\u20136.","journal-title":"Lung Cancer"},{"issue":"9","key":"15916_CR62","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1111\/cas.13721","volume":"109","author":"T Hida","year":"2018","unstructured":"Hida T, Seto T, Horinouchi H, et al. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9. Cancer Sci. 2018;109(9):2863\u201372.","journal-title":"Cancer Sci"},{"issue":"3","key":"15916_CR63","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jtho.2020.11.004","volume":"16","author":"M Nishio","year":"2021","unstructured":"Nishio M, Yoshida T, Kumagai T, et al. Brigatinib in Japanese patients with ALK-Positive NSCLC previously treated with alectinib and other tyrosine kinase inhibitors: outcomes of the phase 2 J-ALTA Trial. J Thorac Oncol. 2021;16(3):452\u201363.","journal-title":"J Thorac Oncol"},{"issue":"22","key":"15916_CR64","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with Crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II Trial. J Clin Oncol. 2017;35(22):2490\u20138.","journal-title":"J Clin Oncol"},{"issue":"12","key":"15916_CR65","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654\u201367.","journal-title":"Lancet Oncol"},{"key":"15916_CR66","doi-asserted-by":"crossref","first-page":"905947","DOI":"10.3389\/fphar.2022.905947","volume":"13","author":"D Liao","year":"2022","unstructured":"Liao D, Yu L, Shangguan D, et al. Recent advancements of monotherapy, combination, and sequential treatment of EGFR\/ALK-TKIs and ICIs in non-small cell lung cancer. Front Pharmacol. 2022;13:905947.","journal-title":"Front Pharmacol"},{"issue":"20","key":"15916_CR67","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1200\/JCO.24.00762","volume":"42","author":"DH Owen","year":"2024","unstructured":"Owen DH, Ismaila N, Freeman-Daily J, et al. Therapy for stage IV non\u2013small cell lung cancer with driver alterations: ASCO living guideline, version 2024.1. J Clin Oncol. 2024;42(20):e44\u201359.","journal-title":"J Clin Oncol"},{"issue":"4","key":"15916_CR68","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339\u201357.","journal-title":"Ann Oncol"},{"key":"15916_CR69","volume-title":"Chinese Society of Clinical Oncology (CSCO) Guidelines for the diagnosis and treatment of non-small cell lung cancer, 2024 Edition","author":"Chinese Society of Clinical Oncology Guidelines Working Committee","year":"2024","unstructured":"Chinese Society of Clinical Oncology Guidelines Working Committee. Chinese Society of Clinical Oncology (CSCO) Guidelines for the diagnosis and treatment of non-small cell lung cancer, 2024 Edition. Beijing: People\u2019s Medical Publishing House; 2024."},{"issue":"1","key":"15916_CR70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40169-015-0074-1","volume":"4","author":"MB Carper","year":"2015","unstructured":"Carper MB, Claudio PP. Clinical potential of gene mutations in lung cancer. Clin Transl Med. 2015;4(1):33.","journal-title":"Clin Transl Med"},{"issue":"4","key":"15916_CR71","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358\u201376.","journal-title":"Ann Oncol"},{"key":"15916_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.06.043","volume":"156","author":"YT Lin","year":"2021","unstructured":"Lin YT, Chiang CL, Hung JY, et al. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. Eur J Cancer. 2021;156:1\u201311.","journal-title":"Eur J Cancer"},{"issue":"4","key":"15916_CR73","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jordao M, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933\u201359.","journal-title":"Cancer Discov"},{"issue":"6","key":"15916_CR74","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","volume":"3","author":"A Shiba-Ishii","year":"2022","unstructured":"Shiba-Ishii A, Johnson TW, Dagogo-Jack I, et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer. 2022;3(6):710\u201322.","journal-title":"Nat Cancer"},{"key":"15916_CR75","doi-asserted-by":"crossref","unstructured":"Lee YC, Hsieh CC, Lee YL, et al. Which should be used first for ALK-positive non-small-cell lung cancer: chemotherapy or targeted therapy? A meta-analysis of five randomized trials. Medicina (Kaunas). 2019;55(2):29.","DOI":"10.3390\/medicina55020029"},{"key":"15916_CR76","doi-asserted-by":"crossref","first-page":"959637","DOI":"10.3389\/fonc.2022.959637","volume":"12","author":"M Itchins","year":"2022","unstructured":"Itchins M, Pavlakis N. The quantum leap in therapeutics for advanced ALK\u2009+\u2009non-small cell lung cancer and pursuit to cure with precision medicine. Front Oncol. 2022;12:959637.","journal-title":"Front Oncol"},{"issue":"3","key":"15916_CR77","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/cas.14314","volume":"111","author":"N Yanagitani","year":"2020","unstructured":"Yanagitani N, Uchibori K, Koike S, et al. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Sci. 2020;111(3):932\u20139.","journal-title":"Cancer Sci"},{"issue":"5","key":"15916_CR78","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.cllc.2016.03.005","volume":"17","author":"YT Lin","year":"2016","unstructured":"Lin YT, Yu CJ, Yang JC, et al. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK inhibitor(s) failure in advanced ALK positive non-small-cell lung cancer: analysis and literature review. Clin Lung Cancer. 2016;17(5):e77\u201394.","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"15916_CR79","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/17476348.2020.1721285","volume":"14","author":"JA Pinto","year":"2020","unstructured":"Pinto JA, Raez LE, Domingo G. Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer. Expert Rev Respir Med. 2020;14(4):385\u201390.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"15916_CR80","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12885-024-11916-4","volume":"24","author":"M Zhao","year":"2024","unstructured":"Zhao M, Shao T, Shao H, et al. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis. BMC Cancer. 2024;24(1):186.","journal-title":"BMC Cancer"},{"issue":"5","key":"15916_CR81","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.21037\/jtd-22-1783","volume":"15","author":"J Wei","year":"2023","unstructured":"Wei J, Zhou H, Song Z. Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study. J Thorac Dis. 2023;15(5):2425\u201337.","journal-title":"J Thorac Dis"},{"issue":"2","key":"15916_CR82","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jtho.2016.07.022","volume":"12","author":"K Ito","year":"2017","unstructured":"Ito K, Hataji O, Kobayashi H, et al. Sequential therapy with Crizotinib and Alectinib in ALK-rearranged non-small cell lung cancer-a multicenter retrospective study. J Thorac Oncol. 2017;12(2):390\u20136.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"15916_CR83","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s40273-023-01316-0","volume":"41","author":"DJ Mott","year":"2023","unstructured":"Mott DJ, Schirrmacher H, Al-Janabi H, et al. Modelling spillover effects on informal carers: the carer QALY trap. PharmacoEconomics. 2023;41(12):1557\u201361.","journal-title":"PharmacoEconomics"},{"key":"15916_CR84","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","volume":"340","author":"RD Riley","year":"2010","unstructured":"Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221.","journal-title":"BMJ"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15916-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15916-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15916-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:39:11Z","timestamp":1781775551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15916-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15916"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15916-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"629"}}